Managed Care Update: VASCEPA® (icosapent ethyl) now available (Tier 2) on Express Scripts, Inc. / MEDCO National Formularies
Still don't understand all the AMRN hate....same team who brought Lovaza to market as Reliant before being bought out just gets approved for a better drug with 0 side effects, and so far it's looking good re: ANCHOR indication which would be a market 10x larger than Lovaza's (Lovaza tried and failed to get ANCHOR, they are only approved for MARINE).
Now, first Tier 2 announcement. Sweet. Also wondering if a positive NCE decision will act as a catalyst for a shot squeeze, people seem to be really hung up on it for some reason. Vascepa's patent portfolio is so strong though, it's really kind of silly to worry about NCE.
Who can compete? Lovaza's patent is about to expire and this is a superior drug in every way. Neptune? Please, they are years away from FDA approval, even without the setback of having their production facility explode last November! Merck's Tredaptive niacin debacle? Hah!
I'm sure there are a thousand things that could go wrong, but the risk/reward looks really good at these levels.Edited by javyn - 3/14/13 at 4:43pm